Ke Qiwei, Wang Kai, Fan Min, Li Mengchao, Luo Guanghua, Wang Daming
Department of Emergency, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou 213003.
Department of Urology, Sir Run Run Hospital, Nanjing Medical University, 109 Longmian Road, Jiangning District, Nanjing 211100.
Medicine (Baltimore). 2020 Oct 30;99(44):e22863. doi: 10.1097/MD.0000000000022863.
Recently, increased expression of TET1 has been shown to inhibit tumor development in many studies. Therefore, a meta-analysis was conducted to assess the prognostic role of TET1 in solid tumors.
PubMed, Embase, and the Web of Science (last updated on June 13, 2019) were searched and 16 eligible studies involving 3100 patients were eventually taken forward into the meta-analysis.
Pooled results indicated that higher TET1 expression in cancer tissues was associated with improved overall survival (OS) [hazard ratio (HR) = 0.736, 95% confidence interval (95% CI) = 0.542-0.998, P = .049]. In the subgroup analysis, higher TET1 expression in respiratory tumors (HR = 0.778, 95% CI = 0.639-0.946, P = .012) and breast cancer in Asian patients (HR = 0.326, 95% CI = 0.199-0.533, P < .001) were significantly associated with better OS. In addition, the association between high TET1 expression and prolonged OS was also statistically significant in the following subgroups; data source from samples (HR = 0.561, 95% CI = 0.384-0.819, P = .003), reported in text (HR = 0.539, 95% CI = 0.312-0.931, P = .027), TET1 protein (HR = 0.635, 95% CI = 0.409-0.984, P = .042), Asians (HR = 0.563, 95% CI = 0.376-0.844, P = .005).
This meta-analysis displays that high expression levels of TET1 in tissues is significantly associated with better survival in patients with solid tumors. This finding can be used as evidence to the tone that TET1 may be a useful target for the treatment of patients with solid tumors in the future.
最近，许多研究表明TET1表达增加可抑制肿瘤发展。因此，进行了一项荟萃分析以评估TET1在实体瘤中的预后作用。
检索了PubMed、Embase和Web of Science（最后更新于2019年6月13日），最终纳入16项符合条件的研究，涉及3100例患者进行荟萃分析。
汇总结果表明，癌组织中较高的TET1表达与总体生存期（OS）改善相关[风险比（HR）=0.736，95%置信区间（95%CI）=0.542-0.998，P=0.049]。在亚组分析中，呼吸肿瘤中较高的TET1表达（HR=0.778，95%CI=0.639-0.946，P=0.012）以及亚洲患者乳腺癌中较高的TET1表达（HR=0.326，95%CI=0.199-0.533，P<0.001）与更好的OS显著相关。此外，在以下亚组中，高TET1表达与OS延长之间的关联也具有统计学意义；样本数据来源（HR=0.561，95%CI=0.384-0.819，P=0.003）、文本报道（HR=0.539，95%CI=0.312-0.931，P=0.027）、TET1蛋白（HR=0.635，95%CI=0.409-0.984，P=0.042）、亚洲人（HR=0.563，95%CI=0.376-0.844，P=0.005）。
这项荟萃分析表明，组织中TET1的高表达与实体瘤患者更好的生存率显著相关。这一发现可作为证据表明TET1未来可能是实体瘤患者治疗的有用靶点。
